Dr. Günther Krumpl habilitated from the University of Vienna’s Medical Faculty and Institute of Pharmacology in 1990. His academic career spans over thirty years, during which he worked as a professor and lecturer at the Institute of Pharmacology and the Department of Anaesthesiology and Intensive Care of the Vienna University. He specialized in the fields of cardiovascular pharmacology, CNS pharmacology, muscle relaxants and addiction. His career in the industry includes working for Bayer-, Wellcome-, Glaxo- and Chiesi-Pharmaceuticals. He also received a commercial education at the London Business School. Dr. Krumpl has published more than 50 articles in various leading academic journals and has given more than 100 lectures at international congresses. His contributions to academia have been recognized with the Hoechst Prize and the Prize of the Austrian Chamber of Doctors. In 1995, he co-founded Torrex Pharma GmbH and managed it successfully until its sale to Chiesi Pharmaceuticals in 2001. Over this period, Dr. Krumpl gained extensive experience in business development, commercial expansion, and mergers and acquisitions. At AOP Health, he worked as a consultant for R&D projects; in particular, he counselled the company on the successful Landiolol Program. He was elected as a Board Member and Chief Corporate Development Officer at AOP Health, and recently as a governing board member of AOP Orphan International AG.
Dr. Günther Krumpl
Dr. Günther Krumpl, board member, AOP Health Group, medical doctor, pharmacologist, Associate Professor and entrepreneurial pioneer in the pharmaceutical industry.
AOP Health has international expertise in pharmaceutical and clinical development as well as in distribution and marketing. It offers flexible solutions for in- and out-licensing partnerships.